Business Today: Latest Business News, India economy News, Stock Markets, Sensex, Mutual Funds and Indian Tax

Total 29 results found. Search for [ Gilead COVID-19 drug clinical trial ]

Results 1 to 21 of 29
PB Jayakumar
June 24, 2020
Remdesivir, allowed for emergency use in COVID-19 patients from May 1, is currently given as an injection and can be used only in hospitals

June 23, 2020
Indian drugmakers Hetero Labs and Cipla Ltd on Sunday gained approval to begin selling their generic versions of remdesivir in the country

June 22, 2020
India's Drug Regulator gave permission to Hetero and Cipla to manufacture and market antiviral drug remdesivir for \"restricted emergency use\" on hospitalised COVID-19 patients

Vivek Dubey
New Delhi, June 21, 2020
Gilead Sciences, in May, had extended a voluntary non-exclusive license to Cipla to manufacture and market Cipla's generic version of remedisvir called CIPREMI

PB Jayakumar
June 16, 2020
About six Indian companies like Cipla, Jubilant, Hetero, Syngene, Dr Reddy's and Zydus Cadila were licensed to make and distribute the drug in over 120 geographies

New Delhi, June 15, 2020
Coronavirus vaccine update: The Health Ministry has included the use of antiviral drug Remdesivir as part of its investigational therapy for restricted emergency use

Associated Press
June 13, 2020
Four companies -- Hetero, Jubilant Life Sciences, Cipla and Mylan NV -- with which the original drug maker, Gilead Sciences Inc, have entered into non-exclusive licensing agreements are still awaiting nod from the DCGI for manufacturing and selling of remdesivir in India

New Delhi, June 13, 2020
COVID-19 vaccine and drug latest news update: Gilead Sciences Inc had previously signed pacts with five other companies for manufacturing and sale of remdesivir; here are latest updates from across world on coronavirus vaccine developments

New Delhi, June 11, 2020
Coronavirus vaccine update: Johnson and Johnson has said that it has pushed up clinical trials by two months; Japanese biotech company AnGes Inc expects its coronavirus vaccine to be ready by the first half of 2021 if production and supply goes smoothly

June 10, 2020
Macaques that received remdesivir did not show signs of respiratory disease and had reduced damage to the lungs, according to the study

PB Jayakumar
New Delhi, June 9, 2020
Whether India develops a Covid-19 vaccine/drug or not, Indian companies will be preferred partners for global pharma to make and distribute the life-saving drug globally

June 9, 2020
The Centre has sought stakeholders' comments on the rules in the draft rules within 15 days, following which it will be reviewed for final notification

June 2, 2020
The drug has been allowed for restricted emergency use for treatment of suspected or laboratory-confirmed cases of COVID-19 in adults and children hospitalised with severe symptoms, subject to several safeguards, the source said

May 30, 2020
Gilead Sciences Inc have entered into non-exclusive licensing agreements with pharma firms including three domestic majors Cipla, Jubilant Life Sciences and Hetero for manufacture and distribution of remdesivir

PB Jayakumar
May 27, 2020
Approval to explore new COVID-19 therapies, licensing and supply deals to manufacture drugs to treat the virus and fast approvals for plants under regulatory scanner have turned the fortunes of most of these companies

May 16, 2020
Interest in Gilead's drug has been high given some promising early data and the lack of approved treatments or preventive vaccines for COVID-19, the disease caused by the novel coronavirus

PB Jayakumar
May 15, 2020
NovaLead claims this drug has shown better efficacy than any existing treatments currently being used in COVID-19 treatment across the world

May 12, 2020
The non-exclusive licensing agreement between Jubilant Life Services and Gilead Sciences allows the former to to register, manufacture and sell remdesivir in 127 countries, including India

New Delhi, May 6, 2020
United States has been worst affected nation with 72,275 deaths, followed by the UK, Italy and Spain; as spread of coronavirus shows no sign of slowing down, researchers and various governments are doubling efforts to develop a vaccine

New Delhi, April 30, 2020
Remdesivir is designed to interfere with the way a virus reproduces, thereby stopping it from multiplying inside the body

PAGES 1 OF 2  12